Relationship between thrombin generation parameters and prothrombin fragment 1 + 2 plasma levels

Author(s):  
Marco Capecchi ◽  
Erica Scalambrino ◽  
Samantha Griffini ◽  
Elena Grovetti ◽  
Marigrazia Clerici ◽  
...  
2001 ◽  
Vol 86 (10) ◽  
pp. 991-994 ◽  
Author(s):  
Francesco Casilli ◽  
Emilio Assanelli ◽  
Marco Grazi ◽  
Giancarlo Marenzi ◽  
Maurizio Guazzi ◽  
...  

SummaryRecent clinical trials have demonstrated a better ability of low-molecular-weight heparin, compared to unfractionated heparin, in reducing ischemic cardiac events in patients with acute coronary syndromes without ST-segment elevation. No data are available concerning the in-vivo comparison of enoxaparin and unfractionated heparin on thrombin generation in patients with unstable angina or non-Q-wave myocardial infarction. We measured the plasma levels of prothrombin fragment 1+2 (a marker of prothrombin activation) and thrombin/anti-thrombin complex (a marker of thrombin generation) in 45 patients with non ST-elevation acute coronary syndromes who were randomized to receive enoxaparin, 3000 IU anti-Xa as an i. v. bolus, followed by 70 IU anti-Xa/Kg every 8 h for 3 days (23 pts, Group 1) or a bolus of 100 IU/kg of unfractionated heparin followed by infusion for 3 days titrated to maintain the aPTT between 70 and 90 s (22 pts, Group 2). Plasma levels of prothrombin fragment 1+2 reduced significantly at 3rd h of treatment in both groups (–42% in Group 1 and –45% in Group 2), reached the lowest plasma concentration at the 24th h and exhibited a slight increase at the 72nd h; no differences were observed between the two groups at any time points. Plasma thrombin/antithrombin complex levels had a similar behaviour: reduced markedly in both groups at the 3rd h (–52% in Group 1 and –46% in Group 2), remained lower during the first two days and slightly rose at 72nd h. No differences between the two groups in plasma levels of this marker were apparent during drug infusion. In Group 1 the aPTT did not show significant changes; in Group 2 the mean value of aPTT doubled the basal value at any time point of determination. Both enoxaparin and unfractionated heparin produced a marked and similar reduction of thrombin generation. Other unknown mechanisms might explain the different clinical effects of the two heparins.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3174-3174
Author(s):  
Anita Sylvest Andersen ◽  
Anna-Marie Münster ◽  
Thomas Bergholt ◽  
Isabelle Deltour ◽  
Merete Bak Bertelsen ◽  
...  

Abstract Abstract 3174 Objective: Pregnancy is an acquired hypercoagulable condition as coagulation is shifted towards a more procoagulant state. Prothrombin fragment 1.2 (F1.2) is a direct measure of thrombin generation and thus of activation of the haemostatic system. We aimed to investigate the relationship between plasma F1.2 and urinary elimination in pregnancies complicated by PE compared to uncomplicated normotensive pregnancies and to establish whether levels of urinary F1.2 reflects thrombin generation de facto or is influenced or a result of proteinuria. Methods: In 62 pregnancies with PE and 10 randomly selected normotensive pregnancies, blood samples were collected at inclusion and at gestational weeks 17, 23, 29, 33, 37, 39 and 41, and urine samples were collected every two weeks from inclusion until delivery or in a subgroup of patients only once before delivery. Levels of plasma and urinary F1.2, albumin and creatinine and plasma D-dimer were measured and standardized data collected on pregnancy, delivery, placenta and neonatal outcome. F1.2 in urine and plasma were analyzed by enzyme immunoassay Enzygnost® F1.2 (Dade Behring Marburg GmbH, Germany). All measurements were performed in duplicate and a reference curve established for each series. Creatinine was analyzed by enzymatic reaction IDMS (Isotope Dilution Mass Spectroscopy) by Ortho Clinical (Johnson & Johnson Nordic AB, Sweden), albumin was analyzed by direct immunoassay by Ortho Clinical (Johnson & Johnson Nordic AB, Sweden), and finally D-dimer analyzed by BCSXP (Siemens 2750-DK, reagens Auto Dimer, Biopool, UK). Results: In all pregnancies, levels of urinary F1.2 and plasma F1.2 increased throughout pregnancy until delivery especially in pregnancies complicated by PE (Figure 1). This difference between PE and controls was more pronounced at gestational weeks 30 and 37. D-dimer demonstrated a small increase with gestational age in all pregnancies with non-significant higher measurements in the second and third trimesters of women with PE. Creatinine was fairly constant in all pregnancies. In PE, albuminuria was significantly increased at 30 and 37 gestational weeks, coinciding with declining plasma levels. There was no significant association between levels of urinary F1.2 and albuminuria (Figure 2). Conclusion: In all pregnancies, levels of uF1.2 increased with gestational age with an even further increase at 37 gestational weeks. The increase in urinary F1.2 was even more pronounced in pregnancies with PE, emphasising the hypercoagulable character of this disease. Furthermore, the levels of uF1.2 reflected plasma generation of F1.2 and thus the amount of thrombin generated. F1.2 was eliminated in urine irrespective of the co-existence of proteinuria and urinary F1.2 may be a more reliable and sensitive parameter for assessing haemostatic activation than plasma levels although the exact role of uF1.2 warrants further studies. Disclosures: Lassen: BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Speakers Bureau; Sanofi Aventis: Consultancy; Astellas Pharma: Consultancy; GSK: Consultancy.


1997 ◽  
Vol 78 (05) ◽  
pp. 1327-1331 ◽  
Author(s):  
Paul A Kyrle ◽  
Andreas Stümpflen ◽  
Mirko Hirschl ◽  
Christine Bialonczyk ◽  
Kurt Herkner ◽  
...  

SummaryIncreased thrombin generation occurs in many individuals with inherited defects in the antithrombin or protein C anticoagulant pathways and is also seen in patients with thrombosis without a defined clotting abnormality. Hyperhomocysteinemia (H-HC) is an important risk factor of venous thromboembolism (VTE). We prospectively followed 48 patients with H-HC (median age 62 years, range 26-83; 18 males) and 183 patients (median age 50 years, range 18-85; 83 males) without H-HC for a period of up to one year. Prothrombin fragment Fl+2 (Fl+2) was determined in the patient’s plasma as a measure of thrombin generation during and at several time points after discontinuation of secondary thromboprophylaxis with oral anticoagulants. While on anticoagulants, patients with H-HC had significantly higher Fl+2 levels than patients without H-HC (mean 0.52 ± 0.49 nmol/1, median 0.4, range 0.2-2.8, versus 0.36 ± 0.2 nmol/1, median 0.3, range 0.1-2.1; p = 0.02). Three weeks and 3,6,9 and 12 months after discontinuation of oral anticoagulants, up to 20% of the patients with H-HC and 5 to 6% without H-HC had higher Fl+2 levels than a corresponding age- and sex-matched control group. 16% of the patients with H-HC and 4% of the patients without H-HC had either Fl+2 levels above the upper limit of normal controls at least at 2 occasions or (an) elevated Fl+2 level(s) followed by recurrent VTE. No statistical significant difference in the Fl+2 levels was seen between patients with and without H-HC. We conclude that a permanent hemostatic system activation is detectable in a proportion of patients with H-HC after discontinuation of oral anticoagulant therapy following VTE. Furthermore, secondary thromboprophylaxis with conventional doses of oral anticoagulants may not be sufficient to suppress hemostatic system activation in patients with H-HC.


1983 ◽  
Vol 50 (02) ◽  
pp. 541-542 ◽  
Author(s):  
J T Douglas ◽  
G D O Lowe ◽  
C D Forbes ◽  
C R M Prentice

SummaryPlasma levels of β-thromboglobulin (BTG) and fibrinopeptide A (FPA), markers of platelet release and thrombin generation respectively, were measured in 48 patients within 3 days of admission to hospital for acute chest pain. Twenty-one patients had a confirmed myocardial infarction (MI); 15 had unstable angina without infarction; and 12 had chest pain due to noncardiac causes. FPA and BTG were also measured in 23 control hospital patients of similar age. Mean plasma BTG levels were not significantly different in the 4 groups. Mean plasma FPA levels were significantly higher in all 3 groups with acute chest pain when compared to the control subjects (p < 0.01), but there were no significant differences between the 3 groups. Increased FPA levels in patients with acute chest pain are not specific for myocardial infarction, nor for ischaemic chest pain.


Author(s):  
Michael Metze ◽  
Tristan Klöter ◽  
Stephan Stöbe ◽  
Björn Rechenberger ◽  
Roland Siegemund ◽  
...  

1993 ◽  
Vol 89 (1) ◽  
pp. 22-25 ◽  
Author(s):  
Hidesaku Asakura ◽  
Yoshimune Shiratori ◽  
Hiroshi Jokaji ◽  
Masanori Saito ◽  
Chika Uotani ◽  
...  

2009 ◽  
Vol 102 (11) ◽  
pp. 945-950 ◽  
Author(s):  
Ingvild Agledahl ◽  
Johan Svartberg ◽  
John-Bjarne Hansen ◽  
Ellen Brodin

SummaryMen have a higher incidence of cardiovascular disease (CVD) than women of similar age, and it has been suggested that testosterone may influence the development of CVD. Recently, we demonstrated that elderly men with low testosterone levels had lower plasma levels of free tissue factor pathway inhibitor (TFPI) Ag associated with shortened tissue factor (TF)-induced coagulation initiation in a population based case-control study. Our hypothesis was that one year of testosterone treatment to physiological levels in elderly men would increase the levels of free TFPI Ag in plasma and have a favorable effect on TF-induced coagulation. Twenty-six men with low testosterone levels (≤11.0 nM) were randomly assigned to treatment with intramuscular testosterone depot injections (testosterone undecanoate 1,000 mg) or placebo in a double-blinded study. Each participant received a total of five injections, at baseline, 6, 16, 28 and 40 weeks, and TF-induced thrombin generation ex vivo and plasma free TFPI Ag were measured after one year. At the end of the study total and free testosterone levels were significantly higher in the testosterone treated group (14.9 ± 4.5 nM vs. 8.1 ± 2.4 nM; p<0.001, and 363.3 ± 106.6 pM vs. 187.3 ± 63.2 pM; p<0.001, respectively). Testosterone treatment for one year did neither cause significant changes in TF-induced thrombin generation ex vivo nor changes in plasma levels of free TFPI Ag. In conclusion, normalising testosterone levels by testosterone treatment for 12 months in elderly men did not affect TF-induced coagulation or plasma TFPI levels. The potential antithrombotic role of testosterone therapy remains to be elucidated.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 17-17
Author(s):  
Dougald Monroe ◽  
Mirella Ezban ◽  
Maureane Hoffman

Background.Recently a novel bifunctional antibody (emicizumab) that binds both factor IXa (FIXa) and factor X (FX) has been used to treat hemophilia A. Emicizumab has proven remarkably effective as a prophylactic treatment for hemophilia A; however there are patients that still experience bleeding. An approach to safely and effectively treating this bleeding in hemophilia A patients with inhibitors is recombinant factor VIIa (rFVIIa). When given at therapeutic levels, rFVIIa can enhance tissue factor (TF) dependent activation of FX as well as activating FX independently of TF. At therapeutic levels rFVIIa can also activate FIX. The goal of this study was to assess the role of the FIXa activated by rFVIIa when emicizumab is added to hemophilia A plasma. Methods. Thrombin generation assays were done in plasma using 100 µM lipid and 420 µM Z-Gly-Gly-Arg-AMC with or without emicizumab at 55 µg/mL which is the clinical steady state level. The reactions were initiated with low (1 pM) tissue factor (TF). rFVIIa was added at concentrations of 25-100 nM with 25 nM corresponding to the plasma levels achieved by a single clinical dose of 90 µg/mL. To study to the role of factor IX in the absence of factor VIII, it was necessary to create a double deficient plasma (factors VIII and IX deficient). This was done by taking antigen negative hemophilia B plasma and adding a neutralizing antibody to factor VIII (Haematologic Technologies, Essex Junction, VT, USA). Now varying concentrations of factor IX could be reconstituted into the plasma to give hemophilia A plasma. Results. As expected, in the double deficient plasma with low TF there was essentially no thrombin generation. Also as expected from previous studies, addition of rFVIIa to double deficient plasma gave a dose dependent increase in thrombin generation through activation of FX. Interestingly addition of plasma levels of FIX to the rFVIIa did not increase thrombin generation. Starting from double deficient plasma, as expected emicizumab did not increase thrombin generation since no factor IX was present. Also, in double deficient plasma with rFVIIa, emicizumab did not increase thrombin generation. But in double deficient plasma with FIX and rFVIIa, emicizumab significantly increased thrombin generation. The levels of thrombin generation increased in a dose dependent fashion with higher concentrations of rFVIIa giving higher levels of thrombin generation. Conclusion. Since addition of FIX to the double deficient plasma with rFVIIa did not increase thrombin generation, it suggests that rFVIIa activation of FX is the only source of the FXa needed for thrombin generation. So in the absence of factor VIII (or emicizumab) FIX activation does not contribute to thrombin generation. However, in the presence of emicizumab, while rFVIIa can still activate FX, FIXa formed by rFVIIa can complex with emicizumab to provide an additional source of FX activation. Thus rFVIIa activation of FIX explains the synergistic effect in thrombin generation observed when combining rFVIIa with emicizumab. The generation of FIXa at a site of injury is consistent with the safety profile observed in clinical use. Disclosures Monroe: Novo Nordisk:Research Funding.Ezban:Novo Nordisk:Current Employment.Hoffman:Novo Nordisk:Research Funding.


2020 ◽  
Vol 186 ◽  
pp. 80-85
Author(s):  
Mikkel Lundbech ◽  
Andreas Engel Krag ◽  
Thomas Decker Christensen ◽  
Anne-Mette Hvas

TH Open ◽  
2018 ◽  
Vol 02 (04) ◽  
pp. e350-e356
Author(s):  
Max Friedrich ◽  
Jan Schmolders ◽  
Yorck Rommelspacher ◽  
Andreas Strauss ◽  
Heiko Rühl ◽  
...  

AbstractIn the nonbleeding patient, constant low-level activation of coagulation enables a quick procoagulant response upon an injury. Conversely, local activation of coagulation might influence the systemic activity level of coagulation. To characterize this interaction in more detail, activity pattern analysis was performed in patients undergoing elective surgeries. Blood samples were taken before, during, and 24 hours after surgery from 35 patients undergoing elective minor (n = 18) and major (n = 17) orthopaedic surgeries. Plasma levels of thrombin and activated protein C (APC) were measured using oligonucleotide-based enzyme capture assays, while those of prothrombin fragment 1.2, thrombin–antithrombin-complexes, and D-dimer were measured using commercially available enzyme-linked immunosorbent assays. In vitro thrombin generation kinetics were recorded using calibrated automated thrombography. Results showed that median plasma levels of up to 20 pM thrombin and of up to 12 pM APC were reached during surgery. D-dimer levels started to increase at the end of surgery and remained increased 24 hours after surgery, while all other parameters returned to baseline. Peak levels showed no significant differences between minor and major surgeries and were not influenced by the activity state at baseline. In vitro thrombin generation kinetics remained unchanged during surgery. In summary, simultaneous monitoring of the procoagulant and anticoagulant pathways of coagulation demonstrates that surgical trauma is associated with increased systemic activities of both pathways. Activity pattern analysis might be helpful to identify patients at an increased risk for thrombosis due to an imbalance between surgery-related thrombin formation and the subsequent anticoagulant response.


Sign in / Sign up

Export Citation Format

Share Document